Edition:
United States

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

10.45USD
24 Mar 2017
Change (% chg)

$0.05 (+0.48%)
Prev Close
$10.40
Open
$10.45
Day's High
$10.90
Day's Low
$10.35
Volume
31,456
Avg. Vol
64,527
52-wk High
$13.70
52-wk Low
$7.33

Latest Key Developments (Source: Significant Developments)

Zogenix Q4 loss per share $0.95
Thursday, 9 Mar 2017 04:01pm EST 

Zogenix Inc : Zogenix provides corporate update and reports fourth quarter and full-year 2016 financial results . Q4 loss per share $0.95 . Q4 revenue $11 million . Q4 earnings per share view $-0.84 -- Thomson Reuters I/B/E/S .Q4 revenue view $5.2 million -- Thomson Reuters I/B/E/S.  Full Article

Zogenix receives orphan drug designation in the EU for zx008 in lennox gastaut syndrome
Wednesday, 1 Mar 2017 08:00am EST 

Zogenix Inc : Zogenix Inc- receives orphan drug designation in european union for zx008 in lennox gastaut syndrome .Zogenix Inc- intend to move forward with a phase 3 clinical study for zx008 in lgs in second half of 2017.  Full Article

Perceptive Advisors LLC reports 5.46 pct passive stake in Zogenix
Wednesday, 22 Feb 2017 09:46am EST 

Zogenix Inc :Perceptive Advisors LLC reports 5.46 percent passive stake in Zogenix Inc as of Feb 15 - sec filing.  Full Article

Zogenix amends manufacturing services agreement
Friday, 26 Aug 2016 04:12pm EDT 

Zogenix Inc [ZGNX.O] : Zogenix Inc Co, Patheon UK limited entered into amendment to the manufacturing services agreement, dated February 28, 2013 .The expiration of the term of the services agreement has been retroactively extended from July 31, 2016 to October 31, 2016 - SEC filing.  Full Article

Zogenix Q2 loss per share $0.76
Tuesday, 9 Aug 2016 04:01pm EDT 

Zogenix Inc : Zogenix provides corporate update and reports second quarter 2016 financial results . Q2 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S . Q2 revenue view $5.4 million -- Thomson Reuters I/B/E/S . Q2 loss per share $0.76 . Q2 revenue $2.1 million .Zogenix inc says zogenix is reiterating its previously provided financial guidance for full year 2016.  Full Article

Zogenix to refinance debt, increasing expected 2017 cash balance
Tuesday, 21 Jun 2016 08:00am EDT 

Zogenix Inc : Zogenix announces agreement to refinance debt, further increasing company's expected 2017 cash balance . Continues to expect its cash runway to extend through end of 2017. . Entered into an amendment to its existing term loan facility with oxford finance llc and silicon valley bank . New loan proceeds will increase total amount of term loan principal outstanding to $20 million . Entered into an amendment to provide for new term loans and partially refinance its existing long-term debt under facility . Agreement is expected to result in an increase of approximately $10 million to zogenix's expected cash balance at end of 2017 . Zogenix continues to expect its cash runway to extend through end of 2017 .Term loan facility provides for interest-only payments through feb 2018 followed by consecutive monthly payments of principal and interest until maturity on july 1, 2020.  Full Article

Zogenix Q1 loss per share $0.42
Tuesday, 10 May 2016 04:01pm EDT 

Zogenix Inc : Zogenix Inc says is reiterating its previously provided financial guidance for full year 2016 . Zogenix provides corporate update and reports first quarter 2016 financial results . Q1 loss per share $0.42 . Q1 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S . Q1 revenue $9.2 million .Q1 revenue view $4.9 million -- Thomson Reuters I/B/E/S.  Full Article

Zogenix Inc says FDA asks for more info on late-stage design for ZX008
Sunday, 18 Oct 2015 08:00pm EDT 

Zogenix Inc:Provides regulatory update for zx008.Zx008 is expected to enter phase 3 clinical studies during the fourth quarter of 2015.Announced receipt of request from FDA for additional information related to company's proposed phase 3 program for zx008.Says has responded with the requested information required to initiate the clinical program.Says expected zx008 clinical development timeline remains unchanged.  Full Article

Zogenix, Inc reports positive top-line results from relday Phase 1b Multi-Dose Clinical Trial
Wednesday, 30 Sep 2015 08:00am EDT 

Zogenix, Inc:Reports positive top-line results from Relday(TM) phase 1b multi-dose clinical trial.Says initiates efforts to secure global development and commercialization partner.Says relday was generally safe and well-tolerated.Results were consistent with the profile of risperidone and the company's previous phase 1 single-dose clinical trial.Results for relday demonstrated that risperidone plasma concentrations in the therapeutic range were achieved on the first day of dosing.  Full Article

Zogenix, Inc prices public offering of common stock
Thursday, 30 Jul 2015 08:00am EDT 

Zogenix, Inc:Priced an underwritten public offering of 4,750,000 shares of common stock at a $18.00 per share.Proceeds expected to be about $85.5 million.  Full Article

More From Around the Web

BRIEF-Zogenix Q4 loss per share $0.95

* Zogenix provides corporate update and reports fourth quarter and full-year 2016 financial results